Delivery Order SPE2DB24D1201-SPE2DB25FJDHR
- Not listed
- The Defense Logistics Agency awarded a $3,425.95 firm fixed price delivery order to AmerisourceBergen Drug Corp for Esbriet (pirfenidone) 801 mg tablets in a quantity of 90 units. This award, issued on July 21, 2025, with an ultimate completion date of August 11, 2025, represents a non-competitive delivery order under AmerisourceBergen's existing federal contract vehicle. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg on July 30, 2025, with an ultimate completion date of August 20, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Esbriet 801 mg on August 28, 2025, with completion targeted by September 19, 2025. This competitively awarded, firm fixed-price contract was issued without set-aside provisions and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract utilizes no set-aside designation and represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The pharmaceutical will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Esbriet (pirfenidone) 801 mg tablets in a 90-count quantity. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 13, 2025, and performance location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply contract vehicle with DLA, enabling the company...
- The Defense Logistics Agency issued a delivery order on June 16, 2025, to AmerisourceBergen Drug Corp for the supply of Esbriet (pirfenidone) 267 mg tablets in a quantity of 270 tablets, with a ceiling value of $3,425.95. This order is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 9, 2025....
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp on June 27, 2025, for 90 tablets of Esbriet 801 mg, a pharmaceutical treatment for idiopathic pulmonary fibrosis. This firm fixed-price delivery order, with an ultimate completion date of July 21, 2025, was competitively awarded without a set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Esbriet (pirfenidone) 267 mg tablets in a quantity of 270 units. This non-set-aside, competitively awarded contract carries a firm fixed price structure with an ultimate completion date of October 8, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 90 tablets of Esbriet 801 mg on August 6, 2025, with an ultimate completion date of August 27, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Esbriet (pirfenidone) is a pharmaceutical treatment for idiopathic pulmonary fibrosis, a serious lung condition,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Esbriet 801 mg tablets (90-count units) with a contract ceiling value of $3,425.95. This non-set-aside, competitively awarded delivery order carries firm fixed pricing and is scheduled for completion by June 3, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued under...
- SPE2DB24D1201Indefinite Delivery Contract
- SPE2DB24D1201-SPE2DB25FJDHRDelivery Order
The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for Esbriet 801 mg tablets (90-count supply) on July 7, 2025, with an ultimate completion date of July 28, 2025. This is a competitively awarded, firm fixed-price contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion comprehensive pharmaceutical prime vendor agreement running through December 2026 that supports military healthcare systems globally. AmerisourceBergen Drug Corp serves as a major pharmaceutical distributor for federal medical procurement, particularly supporting Defense Health Agency and other military healthcare customers through its expansive contract portfolio with the Defense Logistics Agency. Esbriet (pirfenidone) is a specialty pharmaceutical used to treat idiopathic pulmonary fibrosis, reflecting the company's role in supplying specialized medications across multiple therapeutic domains. The competitive award demonstrates AmerisourceBergen's continued capability to meet federal procurement requirements and its significant role within the DLA's pharmaceutical supply chain infrastructure supporting military personnel and veterans.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 7/7/25 |